In a report released on August 15, Mani Foroohar from SVB Securities reiterated a Hold rating on Talaris Therapeutics (TALS - Research Report), with a price target of $7.00. The company's shares closed yesterday at $4.22.Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals. According to TipRanks, Foroohar has an average return of -12.9% and a 42.78% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Talaris Therapeutics with a $8.67 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $17.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-hold-rating-on-talaris-therapeutics-tals?utm_source=advfn.com&utm_medium=referral
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.